Anteris Technologies Global Corp. (AVR) is a publicly traded company in the Healthcare — Medical - Devices industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Anteris Technologies Global Corp. is a structural heart innovator dedicated to discovering, developing, and bringing to market medical devices that enhance the well-being of patients grappling with aortic stenosis. The company's premier offering is the DurAVR transcatheter heart valve system, a pioneering transcatheter aortic valve engineered to treat aortic stenosis by precisely emulating the performance of a healthy human aortic valve.
Analysis Summary
Anteris Technologies Global Corp. reported revenue of $1.9M in the most recent fiscal year, growing at a 5-year CAGR of -18.9%.
Trailing-twelve-month margins: gross margin 37.0%, operating margin -47.4%, net margin -46.2%.
At the current price of $8.42, AVR has negative trailing earnings (P/E not meaningful) and an ROE of -77.66%. Market capitalisation stands at $819M.
Balance sheet quality for AVR: current ratio of 0.7, net cash position of $10.3M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $8.42 |
| Market Cap | $819M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 3.24 |
| EV / EBITDA | -5.56 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -77.66% |
| Return on Invested Capital | -41.63% |
| Return on Assets | -38.01% |
| Gross Margin | 36.98% |
| Operating Margin | -4738.36% |
| Net Margin | -4619.67% |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 14.20 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -31.49 |
What to look at in Healthcare / Pharma
The R&D pipeline is the invisible asset. Patents expiring = revenues evaporating. Look at innovation and cash flow.
- R&D / Revenue — Shows investment in future pipeline. Serious pharma reinvests 15-20%
- 5y EPS growth — After patent expirations, are they still growing?
- Gross margin — Branded pharma >70%. Generics much lower — defines the business type
- FCF / Net Income — Earnings quality — big pharma should convert >90%
- ROIC — Capital reinvested efficiently — key in pharma due to long R&D cycles
- Net debt / EBITDA — Pharma acquisitions pile up debt — watch the post-M&A picture
- P/E vs own 10y history — The best comparison is with its own history, not with peers
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| AVR | Anteris Technologies Global Corp. | $814M | 3.24 | -77.7% | |
| ABT | Abbott Laboratories | $177.1B | 32.49 | 3.45 | 10.5% |
| 0Y6X.L | Medtronic Plc | $125.7B | |||
| MDT | Medtronic plc | $118.5B | 22.97 | 2.39 | 10.6% |
| SYK | Stryker Corporation | $109.2B | 29.95 | 4.66 | 16.4% |
| 0R2S.L | Stryker Corporation | $107.9B | 29.27 | 4.55 | 16.4% |
| 0HOY.L | Boston Scientific Corporation | $66.5B | 48.91 | 5.86 | 11.9% |
| BSX | Boston Scientific Corporation | $65.3B | 17.73 | 2.61 | 14.9% |
Price Performance
| 1 month | -12.11% |
| 3 months | -13.91% |
| Year-to-date | +68.74% |
| 1 year | +50.09% |
52-Week Range
| 52-week High | $11.06 |
| 52-week Low | $3.30 |
| Avg Volume (90d) | 1.1M |
Related companies: ANIK · ARAY · ATLN · CYBN · LNSR · LUCD · MXCT
Explore sector: Healthcare · Medical - Devices
More sections of AVR: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks